Chronic Myeloid Leukemia
US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.
The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic PhaseFebruary 09, 2017
Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.
Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.
Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.
In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.
Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).
With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.
During the summer, many patients with CML who are taking oral chemotherapy drugs have questions about taking their drugs while traveling. What advice can we give them regarding this?
Lymphocytosis is associated with higher response rates, significantly longer response durations, and improved overall survival.
Dasatinib, nilotinib, and ponatinib, used in the treatment of patients with chronic myeloid leukemia (CML) increase vascular occlusive events.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Nearly 25 percent of patients with chronic myeloid leukemia (CML) undergoing treatment with tyrosine kinase inhibitors are vulnerable to a a "withdrawal syndrome," a recent study reported.
Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
New research indicates that patients with chronic-phase chronic myeloid leukemia with deep molecular responses to TKIs have increased effector natural killer and cytotoxic T cell immune responses to leukemia-associated antigens.
Bosutinib continues to demonstrate durable long-term efficacy and manageable toxicity in patients with chronic myeloid leukemia (CML).
Patients with chronic myeloid leukemia who received imatinib plus pioglitazone achieved a sustained complete molecular response for up to 4.7 years after the withdrawal of the antidiabetes medication.
Tyrosine kinase inhibitors (TKIs) seem safe in patients with chronic myeloid leukemia (CML) in chronic-phase and chronic kidney disease.
What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?
The FDA asked the manufacturer of ponatinib (Iclusig) to suspend marketing and sales of the drug, hydrocodone bitartrate extended-release capsules (Zohydro ER) gained FDA approval, and other FDA actions.
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anticancer drugs, according to new research.
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- FDA Discontinues ESA APPRISE Risk Evaluation and Mitigation Strategy Program
- Vitamin D Supplementation is Recommended for Pediatric Patients With Sarcoma
- Extended Adjuvant Therapy for Breast Cancer Improves 5-Year Disease-free Survival
- A Structured Group Exercise Program for Patients With Metastatic Cancer Receiving Chemotherapy and CTNNB1 (β-catenin) as a Biomarker of Exercise Efficacy
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|